GS-0976 (Firsocostat): an investigational liver-directed acetyl-CoA carboxylase (ACC) inhibitor for the treatment of non-alcoholic steatohepatitis (NASH)

INTRODUCTION: De novo lipogenesis (DNL) plays a major role in fatty acid metabolism and contributes significantly to triglyceride accumulation within the hepatocytes in patients with nonalcoholic steatohepatitis (NASH). Acetyl-CoA carboxylase (ACC) converts acetyl-CoA to malonyl CoA, and is a rate-c...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Expert Opin Investig Drugs
Huvudupphovsmän: Alkhouri, Naim, Lawitz, Eric, Noureddin, Mazen, DeFronzo, Ralph, Shulman, Gerald I.
Materialtyp: Artigo
Språk:Inglês
Publicerad: 2019
Ämnen:
Article
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC7063378/
https://ncbi.nlm.nih.gov/pubmed/31519114
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/13543784.2020.1668374
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk